Evolus Inc. (EOLS)
9.76
0.29 (3.06%)
At close: Jan 15, 2025, 10:22 AM
Company Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus Inc.
| Country | United States |
| IPO Date | Feb 8, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 322 |
| CEO | David Moatazedi |
Contact Details
Address: 520 Newport Center Drive Newport Beach, California United States | |
| Website | https://www.evolus.com |
Stock Details
| Ticker Symbol | EOLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001570562 |
| CUSIP Number | 30052C107 |
| ISIN Number | US30052C1071 |
| Employer ID | 46-1385614 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Moatazedi | President, Chief Executive Officer & Director |
| Sandra Beaver | Chief Financial Officer |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development |
| Jeffrey J. Plumer | General Counsel |
| Jessica Novak | Senior Vice President of Human Resources |
| Kurt Knab | Vice President of Sales |
| Nareg Sagherian | Head of Global Investor Relations & Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | 4 | Filing |
| Dec 26, 2024 | 4 | Filing |
| Dec 26, 2024 | 4 | Filing |
| Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | S-8 | Filing |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |